UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000009108 |
|---|---|
| Receipt number | R000010681 |
| Scientific Title | A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer. |
| Date of disclosure of the study information | 2012/10/17 |
| Last modified on | 2024/03/21 11:16:16 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2012/10/13 16:45:57 | ||
| 2 | Update | 2012/10/15 21:15:31 | Interventions/Control_1 Key exclusion criteria |
|
| 3 | Update | 2012/10/15 21:17:46 | Key inclusion criteria |
|
| 4 | Update | 2013/10/14 16:37:27 | TEL Last name of contact person Last name of contact person TEL |
|
| 5 | Update | 2015/10/21 09:20:15 | Last name of lead principal investigator Last name of lead principal investigator Last name of contact person Last name of contact person Name of person sending information Name of person sending information |
|
| 6 | Update | 2017/04/18 07:26:50 | Name of primary person or sponsor Organization |
|
| 7 | Update | 2024/03/21 10:50:22 | Recruitment status Date of IRB Last follow-up date |
|
| 8 | Update | 2024/03/21 11:16:16 | Date of IRB |
